Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

502 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
Zittoun R, Liso V, Mandelli F, Rotoli B, de Witte T, Gattringer C, Resegotti L, Caronia F, Leoni P, Petti MC, et al. Zittoun R, et al. Among authors: de witte t. Leukemia. 1992;6 Suppl 2:76-7. Leukemia. 1992. PMID: 1578949 Clinical Trial. No abstract available.
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, et al. Zittoun RA, et al. Among authors: de witte t. N Engl J Med. 1995 Jan 26;332(4):217-23. doi: 10.1056/NEJM199501263320403. N Engl J Med. 1995. PMID: 7808487 Free article. Clinical Trial.
[Comparison between intensive consolidation by bone marrow autograft or by chemotherapy of acute myeloblastic leukemias in 1st complete remission: AML8A protocol of the Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC)].
Zittoun R, Rio B, Delmer A, Vekhof A, Mandelli F, Willemze R, de Witte T, Tura S, Ferrini PR, Stryckmans P, et al. Zittoun R, et al. Among authors: de witte t. Nouv Rev Fr Hematol (1978). 1993 Feb;35(1):15-6. Nouv Rev Fr Hematol (1978). 1993. PMID: 8511034 Clinical Trial. French. No abstract available.
Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups.
Keating S, Suciu S, de Witte T, Mandelli F, Willemze R, Resegotti L, Broccia G, Thaler J, Labar B, Damasio E, Bizzi B, Rotoli B, Vekhoff A, Muus P, Petti MC, Dardenne M, Solbu G, Vegna ML, Zittoun RA. Keating S, et al. Among authors: de witte t. Bone Marrow Transplant. 1996 Jun;17(6):993-1001. Bone Marrow Transplant. 1996. PMID: 8807105 Clinical Trial.
Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
Zittoun R, Mandelli F, Willemze R, de Witte T, Tura S, Ferrini PR, Stryckmans P, Gattringer C, Petti MC, Solbu G, et al. Zittoun R, et al. Among authors: de witte t. Leukemia. 1992;6 Suppl 2:114-5. Leukemia. 1992. PMID: 1578909 Clinical Trial. No abstract available.
Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, Petti MC, Willemze R. Zittoun R, et al. Among authors: de witte t. J Clin Oncol. 1996 Jul;14(7):2150-9. doi: 10.1200/JCO.1996.14.7.2150. J Clin Oncol. 1996. PMID: 8683249 Free article. Clinical Trial.
The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial.
Keating S, Suciu S, de Witte T, Zittoun R, Mandelli F, Belhabri A, Amadori S, Fibbe W, Gallo E, Fillet G, Varet B, Meloni G, Hagemeijer A, Fazi P, Solbu G, Willemze R; EORTC Leukemia Group; GIMEMA Leukemia Group. Keating S, et al. Among authors: de witte t. Leukemia. 2003 Jan;17(1):60-7. doi: 10.1038/sj.leu.2402782. Leukemia. 2003. PMID: 12529661 Free article. Clinical Trial.
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921).
Oosterveld M, Suciu S, Verhoef G, Labar B, Belhabri A, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Zittoun R, Hess U, Anak O, Beeldens F, Willemze R, de Witte T. Oosterveld M, et al. Among authors: de witte t. Leukemia. 2003 May;17(5):859-68. doi: 10.1038/sj.leu.2402897. Leukemia. 2003. PMID: 12750698
502 results